Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the Phase 1a/b EMBER study
Key Abstracts/Publication in ER+ve Breast Cancer
Chairpersons :
Dr. K Sambasivaiah, Dr. Anand Pathak
Speaker :
Dr. Kripa Bajaj